Baillie Gifford, Franklin Templeton, Google, Novo and T. Rowe Price led a $200m Series G-2 round in Tempus Labs, a provider of artificial intelligence and precision medicine. "Never before has the need to bring the power and promise of technology to healthcare been more acute than it is today. As a leader in this space, we are very much aware of our responsibility and the power of this moment in time; one in which we now possess the technological capability to use artificial intelligence to eradicate disease and help people live longer and healthier lives," Eric Lefkofsky, Tempus Founder and CEO.